Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01626456 · ClinicalTrials.gov registry record · Phase 3
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 478
- Enrollment target
NCT01626456: Completed Phase 3 study, sponsored by Alkermes.
NCT01626456 is a Phase 3 study that has completed, run by Alkermes. The registered enrollment target is 478 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01626456, a Phase 3 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 478 participants
- Enrollment target
Study Summary
This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.
Primary Outcome
This measure includes incidences \>5%.
Interventions
- DRUG ALKS 9072, Low
- DRUG ALKS 9072, High
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
What the finished NCT01626456 record still lists
NCT01626456 is an interventional study that assigns participants to a tested intervention. The registered 478 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 2 interventions - of which ALKS 9072, Low is the first listed.
NCT01626456 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01626456 about?
NCT01626456 is a clinical study titled "A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)". This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.
What is the current status of trial NCT01626456?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 478 participants. The study started on 2012-06. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01626456?
The interventions under investigation include: ALKS 9072, Low (DRUG), ALKS 9072, High (DRUG).
Who is sponsoring clinical trial NCT01626456?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01626456's enrollment target sits among peer trials
478 805th of 2000 higher than 1,194 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05446272 · 478 participants · NA
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
- NCT06172296 · 478 participants · Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- NCT04221542 · 479 participants · Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia